U.S. Markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    52.16
    -0.20 (-0.38%)
     
  • Gold

    1,828.10
    -1.80 (-0.10%)
     
  • Silver

    24.84
    -0.02 (-0.08%)
     
  • EUR/USD

    1.2092
    -0.0072 (-0.5925%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • Vix

    24.34
    +1.09 (+4.69%)
     
  • GBP/USD

    1.3593
    -0.0047 (-0.3412%)
     
  • USD/JPY

    103.8410
    -0.0010 (-0.0010%)
     
  • BTC-USD

    36,211.39
    +1,210.73 (+3.46%)
     
  • CMC Crypto 200

    701.93
    -33.21 (-4.52%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,519.18
    -179.12 (-0.62%)
     

PACT Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference

·1 min read

SOUTH SAN FRANCISCO, Jan. 11, 2021 /PRNewswire/ -- PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors, today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being held virtually, on January 11, 2021 at 7:30 a.m. PT/10:30 a.m. ET.

(PRNewsfoto/PACT Pharma,Lyell Immunopharma)
(PRNewsfoto/PACT Pharma,Lyell Immunopharma)

About PACT Pharma
PACT is a clinical-stage biopharmaceutical company pioneering individualized, non-viral precision genome engineered, tumor-specific T cell therapies for the treatment of patients with solid cancers. PACT is now enrolling patients in its first-in-human Phase 1 clinical trial.

Each person's cancer emerges with a private signature of mutations. PACT identifies these cancer mutation targets (neoantigens) for each person, biochemically verifies and captures T cells from their blood and uses its proprietary, cutting edge (non-viral) precision genome engineering technologies to manufacture a personalized immune cell therapy product for each person with cancer.

For more information please visit www.pactpharma.com.

Media Contact

Sarah Sutton
Finsbury Glover Hering (FGH)
ssutton@fgh.com
202-337-0808

Investor Contact

Uneek Mehra
umehra@pactpharma.com

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/pact-pharma-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301205607.html

SOURCE PACT Pharma